Phase 1 N=21 MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
HIV-1-infection
Primary: Number of Participants With Treatment-Emerging Adverse Events — 1; 1; 4; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=66 A Pilot Study to Assess the Effectiveness and Safety of Belotero Balance® Injection for Volume Augmentation of the Infraorbital Hollow
Correction of Volume Loss in the Infraorbital Hollow Area
Primary: Responder Rate Compared to the Untreated Control Group According to the Merz Infraorbital Hollow Assessment Scale (MIHAS). — 81.6; 9.5 percentage of participants — p=<…
Phase 2 N=152 Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
Locally Advanced Papillary Renal Cell Carcinoma · Metastatic Papillary Renal Cell Carcinoma · Stage III Renal Cell Cancer AJCC v7
Primary: Progression Free Survival (PFS) — 5.6; 9.0; 2.8; 3.0 months — p=0.019
Phase 2 N=56 Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer
Pancreatic Cancer
Primary: Number of Patients Experiencing a Grade 3 or Above Treatment- Related Toxicity — 1; 5 Participants
Phase 2 N=305 Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED)
Dry Eye
Primary: Symptom Assessment in Dry Eye (SANDE) Questionnaire — -25.66; -25.14; -29.95; -24.81 units on a scale
Phase 2 N=25 Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis
Plaque Psoriasis
Primary: The Change From Baseline as Assessed on the Investigator's Global Assessment (IGA) Score. — -0.8; -1.0; -0.6; -0.8 score on a scale — p=0.022
Phase 3 N=301 Azithromycin for Uncomplicated Severe Acute Malnutrition in Burkina Faso (Pilot)
Uncomplicated Severe Acute Malnutrition
Primary: Weight Gain — 1.8; 2.0 g/kg/day
N/A N=17 Adapted ACHIEVE Curriculum for Community Mental Health Settings
Obesity · Mental Disorders, Severe
Primary: Participants With Serious Mental Illness Satisfaction With ACHIEVE Curriculum as Assessed by a Yes Response to Two Questions — 12; 13 Participants
N/A N=107 Promoting Adaptive Neuroplasticity in Mild Cognitive Impairment
Mild Cognitive Impairment · Alzheimer's Disease
Primary: Face-name Memory Test Performance — -.28; -.01; -1.29; -1.76 pairs correctly recalled/recognized
N/A N=214 Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm
Colo-rectal Cancer · Polyp of Colon · Adenomatous Polyp of Colon
Primary: Number of Polyps With Complete Resection — 140; 145 Polyps — p=0.424
N/A N=344 Multiple Chronic Conditions for Older Adults
Chronic Disease
Primary: PROMIS Global Health Measure Score — 46.27; 46.21; 44.92; 46.38 T-score
N/A N=227 Evaluation of Prototype Lenses With Experimental UV/HEV Blocker
Visual Acuity
Primary: Overall Quality of Vision Score — 69.3; 69.0 Unit on a scale
Phase 2 N=42 Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans
Opiate Addiction
Primary: Changes in Cue-Induced In-Clinic Craving (From Baseline to Post-cue (30 Minutes), and From Test Day 1 Through Test Day 4 (1 Week)) - Via the Visual Analog Scale for…
Phase 2 N=40 A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy
Corneal Edema
Primary: Central Corneal Thickness (CCT) — -28.4; -20.1 µm — p=0.0021
Phase 2 N=261 A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
Schizophrenia
Primary: Time to Discontinuation Due to Adverse Event (AE) — 93.02; 116.86 days — p=0.184